)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
DSM Firmenich
DSM Firmenich (DSFIR) investor relations material
DSM Firmenich Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary4 Nov, 2026
Executive summary
Q3 continuing-operations LFL sales growth was 5%, volume-led and consistent with YTD performance; all three business units contributed.
Adjusted EBITDA rose 8% LFL to €482m, with margin expanding sequentially to 20.4%.
The 2026–2028 action plan remained on track, focused on growth, margin expansion, cash conversion and cost discipline.
Financial highlights
Q3 continuing-operations sales were €2,368m versus €2,238m; Adjusted EBITDA was €482m versus €458m.
YTD sales were €7,032m versus €6,881m; Adjusted EBITDA was €1,382m versus €1,364m, up 7% LFL.
Q3 growth and profitability improved year over year and were consistent with YTD performance.
Outlook and guidance
FY 2026 LFL sales growth guidance rose to ~5% from 2–4%; Adjusted EBITDA margin guidance remained ~20%.
Q4 conditions were expected to remain supportive, with a solid order book, good start to October, healthy innovation pipeline and high win rates.
Portfolio growth target is 4%–6% annually; margin trajectory is 21% in 2027 with a further step-up in 2028; cash delivery target is 11%–12%.
2027 inflation outlook: ~3% for raw materials and 2%–3% for other costs; pricing, reformulation, growth and efficiency actions are expected to mitigate costs.
Restructuring is on plan, with €50m savings expected in 2027 and ~€50m in 2028; FX is expected to be more neutral in 2027 at current rates.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from DSM Firmenich
- Vitamin headwinds cut FY 2023 EBITDA, but cash flow strengthened and 2024 guidance targets at least €1.9bn.DSFIR
H2 2023 - 5% LFL sales growth, margin gains, and strong outlook with cost actions and dual listing.DSFIRQ2 2026
- Q1 saw 4% LFL sales growth, margin resilience, and strategic capital actions including a dual listing.DSFIRQ1 2026 TU
- 2026–2028 targets: 2%-4% sales growth, 20%-23% EBITDA margin, and €540M share buyback.DSFIRInvestor update
- 3% organic sales growth and resilient margins achieved despite ANH divestment and macro headwinds.DSFIRQ4 2025
- Divesting Animal Nutrition & Health for EUR 2.2bn, launching EUR 0.5bn buyback, and refocusing on core.DSFIRStatus update
- 7% organic sales growth and 29% EBITDA rise in H1 2025, with strong outlook and portfolio actions.DSFIRH1 2025
- Q3 EBITDA up 32% and full-year outlook raised to €2.1bn, driven by growth and higher vitamin prices.DSFIRQ3 2024 TU
- H1 2024 saw higher sales, EBITDA, and guidance, with strong P&B and TTH growth.DSFIRH1 2024
Next DSM Firmenich earnings date
Q4 202618 Feb, 2027
DSM Firmenich
Next DSM Firmenich earnings date
Q4 202618 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
DSM-Firmenich engages in nutrition, health, and sustainable living businesses in Europe, North America, Latin America, China, and internationally. The company’s Human Nutrition & Health segment offers nutritional and pharmaceutical ingredients for infant, medical, sports, clinical, and weight management markets; and premixes for food and beverage manufacturers as well as supplements. Its Performance Materials segment provides resins and compounds to food packaging and medical device industries; engineering plastics for automotive applications; speciality engineering plastics for electronics; resins for architectural applications; and additives and functional solutions for paints, coatings, construction chemicals, adhesives, paper production chemicals, oil field chemicals, supplies inks to the printing industry.